FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely rheumatology, and is applicable for preventing and treating rheumatoid arthritis in a patient. That is ensured by the oral administration of a therapeutically effective amount of calcitonin in the free form or in the form of a salt or a delivery agent specified in a group specified in N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2- hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and their pharmaceutically acceptable salts.
EFFECT: oral introduction promotes improved absorption, more acceptable pharmacokinetic and pharmacodynamic profile and a smaller degree of calcitonin variability, as compared with the other methods of delivery that provides reduced chondrolysis.
8 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2469709C2 |
| CALCITONIN USED AT OSTEOARTHRITIS | 2004 |
|
RU2368390C2 |
| PHARMACEUTICAL COMPOSITIONS FOR PERORAL INTAKE OF PHARMACOLOGICAL ACTIVE SUBSTANCES | 2001 |
|
RU2287999C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING HGH FOR ORAL ADMINISTRATION | 2007 |
|
RU2493868C2 |
| PERORAL INTRODUCTION OF CALCITONIN | 2003 |
|
RU2355417C2 |
| MIMETIC CALCITONIN FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2689551C1 |
| 5-CNAC AS AGENT FOR ORAL DELIVERY OF PARATHYROID HORMONE FRAGMENTS | 2002 |
|
RU2322256C2 |
| ORAL ADMINISTRATION OF PARATHYROID HORMONE AND CALCITONIN | 2002 |
|
RU2300392C2 |
| CRYSTALLINE FORMS OF DISODIUM SALT OF N-(5-CHLOROSALICILOUL-)-8-AMINOCAPRYLIC ACID | 2006 |
|
RU2507196C2 |
| PEPTIDE ANALOGS FOR TREATMENT OF DISEASES AND DISORDERS | 2012 |
|
RU2616511C2 |
